.1) were significantly correlated with incidence of anemia (P < 0.05 
In cancer patients, hemoglobin level declined proggressively after administration of cisplatin, but medullary erythroblastic cellularity was reported normal. 5 Decline of hemoglobin level correlates with decrease of creatinine clearance, indicating an association between the development of anemia and deterioration of kidney tubular function. Those findings implied the etiology of cisplatin-induced anemia as an erythropoietin deficiency state secondary to cisplatininduced nephrotoxicity. 6, 7 Erythropoietin administration is able to correct the resultant anemia and increase quality of life. However, 2040% patients still need to be transfused. 89 Therefore, the use of erythropoietin as a preventive measure, i.e. erythropoietin administration to patients at high risk of developing anemia during chemotherapy, was considered at higher value. Identification of high-risk patients is essential to attain costeffective measures. Besides, identification of anemia risk factors in patients undergoing chemotherapy with cisplatin has a prognostic value for the need of blood transfusions in near future.
2
Previous studies have defined several factors contributing in development of anemia in chemotherapy patients, 10,11 but there is still lack of evidence providing risk adjustment for potential confounding comorbid. The present study aims to investigate the development of anemia in patients treated with cisplatinbased chemotherapy, as well as to analize in a comprehensive fashion the interaction between factors contributing to the risk of anemia, and to define independent risks of cisplatininduced anemia.
METHODS
This study included 86 nasopharyngeal cancer patients admitted to Oncology Unit, Sardjito Hospital, Jogja karta, Indonesia between December 2002 and December 2005. Data was obtained from two previous studies conducted in Sardjito Hospital.
12,13 There were 139 subjects at initial selection, 135 among them have evaluable clinical data. Only 91 patients completing at least three chemotherapy courses were included in the study. Among them, 86 subjects met the inclusion criteria, i.e. patients who did not have anemia at the beginning of chemotherapy, defined as hemoglobin level less than 11 g/dL. Their characteristics are shown in table 1. was given on day 1 and 8 every 3 weeks. 12 In cisplatin 5FU regimen, cisplatin was given in 100 mg/m 2 dose on day 1, and 5FU was given on day 1 and 5 every 3 weeks.
13
In this cohort study, 14 patients' data were obtained from a case report form of two previous studies conducted in Sardjito Hospital, Jogjakarta, Indonesia. The outcome was incidence of anemia, defined as decrease in blood hemoglobin to a level less than 11 g/dL on any course among the first three observed. Every patient was only counted once. Considered as exposures were age > 55 years old, female sex, baseline hemoglobin level ≤ 13 g/dL, and baseline creatinine clearance < 50 mL/min. Creatinine clearance was estimated according to the CockroftGault formula for creatinine clearance.
Data was analyzed with EpiInfo version 6. Hemoglobin level was observed in every cycle, and paired ttest was used to determine the significant decline in mean hemoglobin levels. Univariate analysis for anemia risk factors was performed with chi 2 test. To eliminate confounding factors, baseline hemoglobin level and baseline creatinine clearance level were stratified for patients' age and sex, using Mantel Haenszel chi 2 test. A multivariate logistic regression was performed to define independent predictors of anemia. P value < 0.05 was considered significant.
RESULTS
At the beginning of chemotherapy, all patients have hemoglobin level above 11 g/dL, therefore no anemia was observed. After first course, 8 (9.3%) patients became anemic, no moderatesevere anemia according to WHO classification, i.e. hemoglobin level < 9.5 g/dL, was observed. Hence either incidence and prevalence on first cycle was 9.3%. Prevalence of anemia increased on second course (17.4%) and third course (27.9%). Moderatesevere anemia was experienced by 3 (3.5%) patients on second course, and 5 (5.8%) patients on third course of chemotherapy. Overall incidence of anemia during three chemotherapy courses was 26 (30.2%). Of 26 patients, 9 (34.6%) had onset of anemia on third course, 9 (34.6%) on the second. Thus incidence of anemia in this study was 9.3% on first course, 11.5% on second course, and 13.1% on third course. Prevalence and incidence of anemia are shown in figure 1. To understand the development of anemia, the alterations of mean hemoglobin levels before and after every chemotherapy course were observed. Paired ttest results are shown in table 2. Before chemotherapy, mean hemoglobin level was 13.3 g/dL, with the range of 11.0 to 16.6 g/dL. This level decline accumulatively during subsequent courses, as shown in figure 2. Overall decrease was significant (P < 0.001) with a difference 1.55 g/dL from baseline level. Decrease of hemoglobin was significant for course 1, 2, and 3, with most prominent decline on first course, which differed 0.75 g/dL from baseline. From univariate analysis results as shown in table 3, age > 55 years old (RR = 2.2, 95% CI, 1.24.0), female sex (RR = 2.0, 95% CI, 1.23.8), baseline Hb level ≤ 13 g/dL (RR = 4.2, 95% CI, 1.9-9.4) and baseline CrCl < 50 mL/menit (RR = 2.9, 95% CI, 1.75.1) have 
Chemotherapy course
Prevalence of anemia Incidence of anemia significant correlation with the incidence of anemia (P < 0.05). P value was not significant (> 0,05) for presence of distant metastases in this study.
Age and sex were wellknown as factors associated with baseline hemoglobin and baseline creatinine clearance. 16, 17 Therefore, stratification was performed on baseline hemoglobin level and baseline creatinine clearance for patients' age and sex to eliminate confounding effects and to calculate the actual risk. The results are shown in table 4. On stratification based on patients' sex, baseline creatinine clearance less than 50 mL/min still significantly correlated with the risk of anemia, however, there is a difference in risk calculated after stratification, implying some degree of confounding. On stratification based on patients' age, there was a substantial confounding observed, indicated by more than 10% difference between adjusted risk and the initially calculated risk, thus the correlation between baseline creatinine clearance with incidence of anemia became insignificant. Patients' age and sex confound the relationship between baseline creatinine clearance and incidence of anemia, therefore baseline creatinine clearance less than 50 mL/min was a weak risk factor for cisplatininduced anemia.
In multivariate analysis as shown in table 5, among age, sex, baseline hemoglobin level and baseline creatinine clearance, only two were recognized as independent risk factors of anemia, those were baseline hemoglobin level 13 g/dL and less (P < 0.001) and baseline creatinine clearance less than 50 mL/min (P < 0.05). Baseline hemoglobin level ≤ 13 g/dL was the strongest risk factor for cisplatininduced anemia. 
DISCUSSION
This study was intended to identify risk factors of cisplatininduced anemia. In univariate analysis, age > 55 years old, female sex, baseline hemoglobin level ≤ 13 g/dL, and baseline creatinine level < 50 mL/min were correlated significantly with incidence of anemia. Occurrence of distant metastases was not significantly correlated with anemia. This finding is similar to previous study which stated that metastases did not have significant correlation with nadir of hemoglobin post chemotherapy with cisplatin 10 . On the other side, a recent study 16 mentioned that occurrence of metastases was an independent risk factors of severe anemia on patients treated with cytotoxic chemotherapy (OR = 2.8; 95% CI = 1.2-7.1). Those difference may be caused by different characteristics of subjects included. In this study, the most prominent decline of hemoglobin occurred after first course of chemotherapy, while in previous study, hemoglobin level fell most markedly after third course of cisplatinbased chemotherapy. 6 Baseline hemoglobin level 13 g/dL and less was reported to correlate with risks of severe chemotherapy associated anemia.
16 Similar finding was noted in this study, where hemoglobin level ≤ 13 g/dL was defined as risk factor for anemia (RR = 4.2; 95% CI = 1.99.4). Several other studies also establish baseline hemoglobin level as risk factor for anemia with different cutoffs, such as hemoglobin level less than 12 g/dL 18 and low normal hemoglobin level, i.e. 12.013.4 g/dL for male and 12.012.9 g/dL for female, 19 as independent risk factor of chemotherapyinduced anemia.
Patients with age older than 55 years have greater risk of developing anemia (RR = 2.2; 95% CI = 1.24.0). The results confirmed that advanced age was a risk factor for cisplatininduced anemia, as stated by some previous studies. In a study evaluating risk factors of cisplatinassociated anemia, 10 it was reported that the nadir of hemoglobin throughout chemotherapy with cisplatin was significantly lower in patients with age older than 60 years old (P < 0.05), while in National Health And Nutrition Examination Survey III (NHANES III), prevalence of anemia is significantly higher in age population more than 65 years old.
20
Another study 18 reported no association between severe anemia requiring transfusions (SAART) with age in patients undergoing cytotoxic chemotherapy.
In recent study about risk factors of chemotherapy induced anemia, 18 female sex was reported to have significant correlation with severe anemia (P < 0.05), but was not identified as independent risk factor. The present study has similar finding, female sex was correlated with anemia (RR = 2.0; 95% CI = 1.13.8) but was not an independent predictor in multivariate analysis. Another study observed no significant relationship between sex and nadir of hemoglobin after first course of chemotherapy with cisplatin.
10
Baseline creatinine clearance less than 50 mL/min was correlated significantly with incidence of anemia (RR = 2.9; 95% CI = 1.75.1). As a comparison, from the data obtained through NHANES III survey, it was reported 16 that at creatinine clearance level below 50 mL/min, a significant decreace in hemoglobin level was observed in both males and females, only in males this fall of hemoglobin level started at creatinine clearance level less than 70 mL/min. This finding suggested a correlation between sex and baseline creatinine clearance as risk factor of anemia.
In regards of previous studies reporting a relationship between age and sex with baseline hemoglobin level and baseline creatinine clearance, 16,17 stratification analysis were performed to eliminate confounding factors. As the results, both age and sex of patients have confounding effects towards the correlations between baseline hemoglobin level with anemia, and baseline creatinine clearance with anemia as well. For baseline hemoglobin, confounding were only slightly observed, that the adjusted risk calculated was not notably different from initial risk (aRR = 4.1; 95% CI = 1.710.0) and the correlation with anemia remained significant (P < 0.001). In contrast, adjusted risk for baseline creatinine clearance was considerably lower than initial risk (aRR = 2.7; 95% CI = 1.07.6) that the correlation with anemia became insignificant (P > 0.05). This implied creatinine clearance as a weak risk factor.
In multivariate analysis with logistic regression, only baseline hemoglobin level ≤ 13 g/dL (OR = 9.,6; 95% CI = 2.733.3) and baseline creatinine clearance < 50 mL/min (OR = 9.0; 95% CI = 1.1-73.6) were identified as independent predictors, with baseline hemoglobin level as predominant risk factor (P < 0.001). These results were equivalent with prior findings 10 that reported baseline hemoglobin level as independent predictor of nadir of hemoglobin after first course of cisplatinbased chemotherapy, and the recent cohort 11 that denoted baseline hemoglobin level less than 13 g/dL as independent risk factor of chemotherapy associated anemia (OR = 0.55; 95% CI 0.39-0.77). With different cutoffs, other study also reported that hemoglobin level was identified as independent risk factor of severe anemia following chemotherapy (OR = 14.0; 95% CI = 7.030.0). A recent survey in Australia 19 also stated that low normal hemoglobin level was a risk factor of anemia in chemoterapy patients (OR = 5.4; 95% CI = 2.7-10.9).
Most recent study indicated that maintenance of hemoglobin level between 11 to 12 mg/dL is significantly correlated with increased quality of life in cancer patients. 21 This finding gave rise to preventive efforts in order to maintain the level of hemoglobin in desired range. Identification of risk factors is thereby important for high-risk patients who would benefit most from prophylaxis for anemia.
9
There were limitations in this study, such as the predicted value instead of measured actual creatinine clearance, the elimination of risk from both combining cytotoxic agents and dose difference, and the definition of anemia that was limited to decrease of hemoglobin level instead of patients' functional state. For consideration, earlier study reported that there was a significant correlation between the rise of hemoglobin level and improvement of quality of life in cancer patients, 22 hence identification of risk factor of anemia will indirectly promote the preservation of quality of life by maintaining hemoglobin level in desired range, i.e. above 11 g/dL.
21 It is concluded that hemoglobin level in cancer patients undergoing cisplatinbased chemotherapy fell significantly after first course of chemotherapy, and continue to decrease afterward. Baseline hemoglobin level of 13 g/dL and less and baseline creatinine clearance less than 50 mL/min are independent predictors of cisplatin-induced anemia. These findings suggest that both hemoglobin level and creatinine clearance are useful to recognize highrisk patients who might need specific treatment for anemia in the future. By contrary, prevention of cisplatininduced anemia may be accomplished by modifying these baseline characteristic of patients. However, futher studies are needed to establish particular management of cisplatin based anemia based on individual risk assessment.
